Eucrates Biomedical Acquisition Corp. (NASDAQ:EUCR) Short Interest Update

Eucrates Biomedical Acquisition Corp. (NASDAQ:EUCRGet Rating) saw a significant decline in short interest during the month of April. As of April 30th, there was short interest totalling 7,900 shares, a decline of 18.6% from the April 15th total of 9,700 shares. Approximately 0.1% of the company’s shares are short sold. Based on an average trading volume of 10,600 shares, the days-to-cover ratio is currently 0.7 days.

NASDAQ EUCR remained flat at $$9.88 on Tuesday. The company had a trading volume of 53 shares, compared to its average volume of 12,059. Eucrates Biomedical Acquisition has a fifty-two week low of $9.65 and a fifty-two week high of $10.77. The company has a 50 day moving average of $9.86 and a 200 day moving average of $9.83.

A number of large investors have recently bought and sold shares of EUCR. Deerfield Management Company L.P. Series C acquired a new position in Eucrates Biomedical Acquisition in the fourth quarter valued at about $9,760,000. Goldman Sachs Group Inc. grew its stake in Eucrates Biomedical Acquisition by 1,476.7% in the first quarter. Goldman Sachs Group Inc. now owns 553,622 shares of the company’s stock valued at $5,448,000 after acquiring an additional 518,510 shares during the period. D. E. Shaw & Co. Inc. boosted its position in shares of Eucrates Biomedical Acquisition by 172.5% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 478,669 shares of the company’s stock worth $4,672,000 after buying an additional 302,988 shares during the period. Eisler Capital UK Ltd. acquired a new position in shares of Eucrates Biomedical Acquisition during the fourth quarter worth about $2,269,000. Finally, Saba Capital Management L.P. boosted its position in shares of Eucrates Biomedical Acquisition by 379.6% during the first quarter. Saba Capital Management L.P. now owns 270,751 shares of the company’s stock worth $2,670,000 after buying an additional 214,300 shares during the period. 54.48% of the stock is owned by hedge funds and other institutional investors.

About Eucrates Biomedical Acquisition (Get Rating)

Eucrates Biomedical Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.

Recommended Stories

Want More Great Investing Ideas?

Receive News & Ratings for Eucrates Biomedical Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eucrates Biomedical Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.